ProVise Management Group LLC Sells 4,129 Shares of Novartis AG $NVS

ProVise Management Group LLC lowered its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 3.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 129,971 shares of the company’s stock after selling 4,129 shares during the period. Novartis makes up 1.3% of ProVise Management Group LLC’s portfolio, making the stock its 24th biggest position. ProVise Management Group LLC’s holdings in Novartis were worth $18,530,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in NVS. Moors & Cabot Inc. grew its stake in Novartis by 1.9% in the third quarter. Moors & Cabot Inc. now owns 29,315 shares of the company’s stock valued at $4,179,000 after acquiring an additional 545 shares during the period. Valmark Advisers Inc. increased its holdings in Novartis by 4.0% during the 3rd quarter. Valmark Advisers Inc. now owns 8,374 shares of the company’s stock worth $1,194,000 after purchasing an additional 324 shares in the last quarter. Allworth Financial LP increased its holdings in Novartis by 1.6% during the 3rd quarter. Allworth Financial LP now owns 93,900 shares of the company’s stock worth $14,716,000 after purchasing an additional 1,510 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Novartis by 8.0% in the 3rd quarter. Fisher Asset Management LLC now owns 16,762,528 shares of the company’s stock valued at $2,389,834,000 after purchasing an additional 1,239,150 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in shares of Novartis by 148.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 136,987 shares of the company’s stock valued at $19,530,000 after purchasing an additional 81,954 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Performance

Shares of NVS opened at $160.59 on Monday. Novartis AG has a 12 month low of $123.24 and a 12 month high of $170.46. The firm has a fifty day simple moving average of $149.13 and a 200 day simple moving average of $152.60. The stock has a market capitalization of $306.42 billion, a price-to-earnings ratio of 30.65, a PEG ratio of 2.94 and a beta of 0.40. The company has a current ratio of 0.88, a quick ratio of 0.70 and a debt-to-equity ratio of 0.98.

Novartis (NYSE:NVS – Get Free Report) last released its earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.25 by $0.21. Novartis had a net margin of 18.11% and a return on equity of 41.04%. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.53 billion. During the same quarter last year, the firm earned $2.25 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Research analysts forecast that Novartis AG will post 9.10 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on NVS. Weiss Ratings lowered Novartis from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, November 4th. Berenberg Bank decreased their price objective on Novartis from $147.00 to $130.00 and set a “hold” rating for the company in a report on Friday, September 11th. The Goldman Sachs Group reiterated a “sell” rating on shares of Novartis in a report on Monday, September 21st. Wall Street Zen raised Novartis from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Finally, UBS Group restated a “neutral” rating on shares of Novartis in a research note on Wednesday, October 28th. Six analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Novartis currently has an average rating of “Hold” and a consensus target price of $152.25.

Get Our Latest Analysis on Novartis

Novartis Company Profile

(Free Report)

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

Featured Stories

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.